The value of plasma EBV DNA in monitoring the therapeutic effect of nasopharyngeal carcinoma
Zong Jingfeng1, Zheng Yuhong2, Lin Cheng1, Chen Yan2, Chen Chuanben1, Pan Jianji1, Lin Shaojun1
1Department of Radiation Oncology,2Department of Clinical Laboratory, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital,Fuzhou 350014,China
Abstract：Objective To investigate the clinical value of plasma EBV DNA in monitoring clinical efficacy in the treatment of nasopharyngeal carcinoma (NPC). Methods Clinical data of 799 patients initially diagnosed with NPC treated with radical intensity-modulated radiotherapy (IMRT) in our hospital from 2016 to 2017 were analyzed retrospectively. Prior to treatment, the correlation between plasma EBV DNA,clinical stage and tumor progression was analyzed. The relationship between EBV DNA and tumor progression was analyzed after radiotherapy and during follow-up. Results Before IMRT, the level of EBV DNA was positively correlated with both clinical stage and tumor progression (both P<0.001). At 6 to 8 weeks after IMRT, 19(2.3%) patients positive for plasma EBV DNA obtained the worst prognosis and 14 cases had tumor progression. At 6-8 weeks after IMRT, 9 patients were negative for EBV DNA and 3 cases had tumor progression. The tumor progression rate of patients with undetectable plasma EBV DNA at the end of IMRT was only 8.3%(64/772),and the progression-free survival rate significantly differed among three groups (all P<0.05). The sensitivity, specificity and accuracy rates of persistent positive plasma EBV DNA during follow-up were calculated as 77.6%,100% and 98.1%, respectively. Conclusions The level of plasma EBV DNA in patients with NPC is correlated with tumor bearing and tumor progression prior to IMRT. At 6-8 weeks after IMRT, patients who are persistently positive for EBV DNA obtain the worst prognosis and should be given with appropriate adjuvant therapy. The correlation between persistent positive plasma EBV DNA during follow up and tumor progression yields a high accuracy rate, indicating that plasma EBV DNA is a reliable biomarker for monitoring the clinical efficacy after radical treatment for NPC patients.
Zong Jingfeng,Zheng Yuhong,Lin Cheng et al. The value of plasma EBV DNA in monitoring the therapeutic effect of nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(12): 881-884.
[1]Tsao SW,Tsang CM,Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma[J]. Biological Sci,2017, 372(1732):1-15. DOI:10.1098/rstb.2016.0270. [2]Kim KY,Le QT,Yom SS,et al. Current state of PCR-based Epstein-Barr virus DNA testing for nasopharyngeal cancer[J]. J Nat Cancer Inst,2017, 109(4):1-7. DOI:10.1093/jnci/djx007. [3]Prayongrat A,Chakkabat C,Kannarunimit D,et al. Prevalence and significance of plasma Epstein-Barr virus DNA level in nasopharyngeal carcinoma[J]. J Radiat Res,2017,58(4):509-516. DOI:10.1093/jrr/rrw128. [4]Lo YM,Chan AT,Chan LY,et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA[J]. Cancer Res,2000,60(24):6878-6881. https://www.ncbi.nlm.nih.gov/pubmed/11156384. [5]Lin S,Pan J,Han L,et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin[J]. Radiother Oncol,2014, 110(3):385-389. DOI:10.1016/j.radonc.2014.01.011. [6]郑瑜宏,陈岩松,潘建基,等. 三种核酸提取方法用于检测血浆EBV-DNA的性能及应用评价[J]. 中华检验医学杂志,2018,41(1):59-65. DOI:10.3760/cma.j.issn.1009-9158.2018.01.013. Zheng YH,Chen YS,Pan JJ,et al. Three nucleic acid extraction methods were used to detect the performance and application of plasma EBV-DNA[J]. Chin J Laborat Med, 2018,41(1):59-65. DOI:10.3760/cma.j.issn.1009-9158.2018.01.013. [7]Ma BB,King A,Lo YM,et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA,tumor burden,and metabolic activity in advanced nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys,2006, 66(3):714-720. DOI:10.1016/j.ijrobp.2006.05.064. [8]Chan ATC,Hui EP,Ngan RKC,et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy:a randomized controlled trial[J]. J Clin Oncol,2018, JCO (2018)777-847. DOI:10.1200/JCO.2018.77.7847. [9]Twu CW,Wang WY,Chen CC,et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid[J]. Int J Radiat Oncol Biol Phys,2014,89(1):21-29. DOI:10.1016/j.ijrobp.2014.01.052. [10]Huang CL,Sun ZQ,Guo R,et al. Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys,2019,104(2):355-361. DOI:10.1016/j.ijrobp.2019.01.007. [11]Kim KY,Le QT,Yom SS,et al. Clinical utility of Epstein-Barr virus DNA testing in the treatment of nasopharyngeal carcinoma patients[J]. Int J Radiat Oncol Biol Phys,2017,98(5):996-1001. DOI:10.1016/j.ijrobp.2017.03.018. [12]Le QT,Zhang Q,Cao H,et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma[J]. Clin Cancer Res,2013,19(8):2208-2215. DOI:10.1158/1078-0432. CCR-12-3702. [13]Li WF,Zhang Y,Huang XB,et al. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy[J]. Chin J Cancer,2017,36(1):87-88. DOI:10.1186/s40880-017-0256-x. [14]Stevens SJ,Verkuijlen SA,Hariwiyanto B,et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia[J]. J Clin Microbiol,2005,43(7):3066-3073. DOI:10.1128/JCM.43.7.3066-3073.2005.
2019, Vol. 28 
